The FDA has backed a drug from Eli Lily that could slow down the progression of Alzheimer’s disease.

The administration says the drugs benefits for mild dementia patients outweighs the reported risks, like brain swelling and bleeding, which will need to be monitored.

Officials want more research to see if potential patients might require a scan for brain proteins before prescribing the drug, donanemab.

Stanford University researchers, however, believe a brain scan isn’t necessary.

Three deaths have been linked to the drug.

https://www.kcra.com/article/alzheimers-drug-slows-disease-gets-backing-from-fda-advisers/61062804